Literature DB >> 10725855

PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients.

R E Peschel1, T J Robnett, D Hesse, C R King, R D Ennis, P B Schiff, L D Wilson.   

Abstract

Because of the uncertainties regarding the efficacy of postoperative radiation therapy for early prostate cancer, treatment strategies following radical prostatectomy include: (1) observation alone in high-risk patients, (2) adjuvant radiation therapy (PSA undetectable) in high-risk patients, or (3) salvage radiation therapy for biochemical and clinical recurrence. Fifty-two patients treated with postoperative radiation therapy in either an adjuvant setting (13) or for salvage (39) were retrospectively reviewed. The actuarial biochemical disease-free survival (bNED) rates following radiation therapy were calculated using the life-table method. Univariate and multi variate analyses were used to define the clinical factors that predict biochemical failure following postoperative radiation therapy. In addition, the bNED survival rate for 36 high-risk surgery patients who were simply observed following prostatectomy was determined. The 3-year bNED survival rate for the adjuvant radiation group was 85% compared with 27% for salvage radiation and 43% for the observation group. These results are statistically significant. Factors that predict biochemical failure following postoperative radiation therapy include preoperative PSA level, pre-radiation therapy PSA level, and seminal vesicle involvement. At our institutions, adjuvant radiation therapy was a superior strategy compared with either observation alone or salvage radiation therapy for high-risk postoperative prostate cancer patients. Int. J. Cancer (Radiat. Oncol. Invest.) 90, 29-36 (2000). Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725855

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1. 

Authors:  Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

Review 2.  Therapy of recurrent disease after radical prostatectomy in 2007.

Authors:  Rudolf Schwarz; Markus Graefen; Andreas Krüll
Journal:  World J Urol       Date:  2007-02-28       Impact factor: 4.226

3.  Design of curcumin loaded cellulose nanoparticles for prostate cancer.

Authors:  Murali Mohan Yallapu; Mitch Ray Dobberpuhl; Diane Michele Maher; Meena Jaggi; Subhash Chand Chauhan
Journal:  Curr Drug Metab       Date:  2012-01       Impact factor: 3.731

4.  Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer.

Authors:  Shu-Ben Sun; Ping Liu; Fa-Ming Shao; Qi-Long Miao
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 5.  Prostate cancer management: (1) an update on localised disease.

Authors:  S R J Bott; A J Birtle; C J Taylor; R S Kirby
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

6.  Au-Ag assembled on silica nanoprobes for visual semiquantitative detection of prostate-specific antigen.

Authors:  Hyung-Mo Kim; Jaehi Kim; Jaehyun An; Sungje Bock; Xuan-Hung Pham; Kim-Hung Huynh; Yoonsik Choi; Eunil Hahm; Hobeom Song; Jung-Won Kim; Won-Yeop Rho; Dae Hong Jeong; Ho-Young Lee; Sangchul Lee; Bong-Hyun Jun
Journal:  J Nanobiotechnology       Date:  2021-03-12       Impact factor: 10.435

7.  Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience.

Authors:  Laurent Quero; Pierre Mongiat-Artus; Vincent Ravery; Claude Maylin; François Desgrandchamps; Christophe Hennequin
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.